Kornimate/medical-research-clean huggingface dataset:
rhinoplasty and quality of life

Conditions: Rhinoplasty; Quality of Life

Summary: quality of life and satisfaction in aesthetic surgery is still under-evaluated. it is a prospective and multicenter study with a 4 months follow-up of patients under rhinoplasty or rhinoseptoplasty procedure. they will answer to the face-q and nose questionnaires before surgery, one week later and 4 months after the procedure. the aim of the study is to show a significant augmentation of the quality of life scores. at this occasion, the face-q questionnaire has been translated and validated in french

the main objective of this study is to show the efficiency of the rhinoplasty or rhinoseptoplasty procedure on the quality of life in a french population. there are many patients reported outcomes questionnaire in aesthetic surgery but none of them is perfect. the face-q rhinoplasty modules questionnaires is a recent test which has been validated in english but not in french. it is able to evaluate different areas of the quality of life and patient satisfaction. after french validation of the face-q, this study will compare patient satisfaction before and after rhinoplasty or rhinoseptoplasty procedure. there is a lack of studies in the french population about rhinoseptoplasty surgery and quality of life or satisfaction. the goal is to show the interest of a surgery procedure on the feeling of the patients, concerning very different domains of appearance. this could help us to define the preoperative patients who are able to be really improved by this surgery

Eligibility criteria:
inclusion criteria: * at least 18 years old, * patient engaged for surgery procedure of rhinoplasty or rhinoseptoplasty exclusion criteria: * patient with nose surgery medical history, * mental or physical incapacity to answer the questionnaires * antecedent of cervico facial cancer
assessment of response to treatment of osteoporosis with oral bisphosphonates in patients with muscular dystrophy

Conditions: Osteoporosis; Muscular Dystrophy; Cystic Fibrosis

Summary: by supplying an adequate amount of calcium and vitamin d with the addition of weekly bisphosphonate, the investigators will be able to increase bone mass and decrease the incidence of fragility fractures in these children with muscular dystrophy. the investigators think this treatment will also decrease the intensity of pain frequently present in these patients and slow the progression of scoliosis.

children with muscular dystrophy, as well as children with other chronic diseases (e.g. cystic fibrosis, chronic inflammatory arthritis) are at risk to develop fragility fractures both due to the disease itself and to drugs (mostly corticosteroids) used to treat the diseases. in addition, children with muscular dystrophy frequently complain of diffuse pain making daily care more difficult and almost always develop structural scoliosis. the objective of the present protocol is to offer these children a preventive treatment aimed at maintaining or increasing their bone mass. we also propose that maintaining bone mass will decrease fracture rates, as well as pain and the rate of progression of scoliosis. rigorous care to ensure adequate intake of calcium and vitamin d, as well as addition of a weekly bisphosphonate, are the central aspect of the project. in addition, we will monitor to avoid possible side-effects such as hypercalciuria and kidney stones.

Eligibility criteria:
inclusion criteria: * osteoporosis or osteopenia * severe muscular dystrophy or cystic fibrosis * may use corticosteroids exclusion criteria: * inability to consent or to take drugs by mouth

Keywords: osteoporosis severe muscular dystrophy cystic fibrosis
dose response of neural mobilization on hamstring flexibility in low back pain

Conditions: Non-specific Low Back Pain

Summary: this study will be a randomized control trial and will be conducted in riphah international hospital, national orthopedic and specialist hospital, riphah international hospital and chambeli institute of physiotherapy. a sample of 34 participants will be taken. participants will be randomized into group a and group b through lottery method. group a will receive high dose neural mobilization technique, hot pack for 15 minutes, strengthening exercises with 10rep/8sets , strengthening exercises for quadriceps and static stretching exercise for hamstring with 10 rep/8sets, while group b will receive low dose neural mobilization technique with minimal intensity, hot pack: 15 minutes, strengthening exercises with 10rep/4sets. both groups will be given session of 40 min/day, 2 days/week for 4 weeks, assessment will be done at baseline, at the end of 1st week, 2nd week, 3rd week \& at the end of 4th week. the outcome measure will be numeric pain rating scale (nprs), oswestry disability index (odi), active knee extension test (ake) and lumbar flexion by schober method. data will be analyzed be spss 22.


Eligibility criteria:
inclusion criteria: * low back pain \> 3 months * no exercises for last 6 months * non-specific lbp in its sub-acute \& chronic phase exclusion criteria: * specific causes of lbp (disc herniation, lumbar stenosis, spinal deformity, fracture, spondylolisthesis), * central or peripheral neurologic signs * systemic illness (tumor and rheumatologic diseases), * psychiatric and mental deficits. * patients who had undergone operations within 6 months

Keywords: neural mobilization technique oswestry disability index active knee extension test numeric pain rating scale lumbar flexion by schober method
tumour localisation with magnetic clip before neoadjuvant chemotherapy.

Conditions: Breast Conserving Surgery

Summary: the feasibility of the use of magnetic clips for tumour localisation before preoperative chemotherapy in combination with superparamagnetic iron oxide nanoparticles (spio) as tracer for sentinel lymph node (sln) detection and in combination with a magnetic clip in the index lymph node metastasis is studied.

the overall aim is to demonstrate that the use of magnetic clips for tumour localisation before preoperative chemotherapy is feasible at breast cancer surgery and histopathological evaluation in combination with superparamagnetic iron oxide nanoparticles (spio) as tracer for sentinel lymph node (sln) detection, and in combination with a magnetic clip in the index lymph node metastasis if targeted axillary surgery is planned.

Eligibility criteria:
inclusion criteria: 1. age above 18 years 2. planned for preoperative chemotherapy before breast cancer surgery 3. planned breast conserving surgery with targeted axillary dissection or sentinel lymph node biopsy using magnetic technique 4. sln-biopsy with magnetic tracer or targeted axillary dissection using magnetic tracer and magseed 5. signed and dated written informed consent before the start of specific protocol procedures exclusion criteria: 1. pregnant or breast-feeding 2. iron overload disease 3. known hypersensitivity to iron or dextran compounds 4. inability to understand given information and give informed consent or undergo study procedures 5. planned mri control for tumour response during chemotherapy

Keywords: breast cancer tumour localisation magnetic clip magnetic tracer preoperative chemotherapy
efficacy of prednisone in patients with severe systemic atheroembolism (cholesterol cristal embolism)

Conditions: Cholesterol Embolism Systemic

Summary: cholesterol cristal embolization (cce) is an orphan multisystem vascular condition occurring in elderly with severe atherosclerosis. in most patients, avoiding the precipitating factors and combination of statin and ras inhibitor are recommended. the lack of randomized controlled trial in cce precludes significant advances. the investigators decided to assess whether prednisone started early, at mild dosage and for a short period prevents death and progression to end-stage renal failure in patients with severe cce, as compared to placebo.

erosion of atheromatous plaque results in release of cholesterol crystal embolism that ultimately occlude medium-sized arterioles and capillaries of the kidney, skin, gastrointestinal tract and central nervous system. the diagnosis relies on histopathological demonstration of cholesterol cristal embolism in any target organ, or can be assumed if the 3 following criteria are met (1) presence of one or more precipitating factors (2) renal function deterioration in atherosclerotic patients (3) ischemic changes of the extremities or demonstration of retinal cce. despite the dismal prognosis in multisystem cce mortality the optimal treatment remains unknown. in most patients, avoiding the precipitating factors and combination of statin and ras inhibitor are recommended. the benefit of prednisone is uncertain, but its dramatic impact has been underlined in several short retrospective series, even with moderate daily dosage (0,2-0,5 mg/kg). however, adverse side effects of steroid therapy in uremic elderly with cce have not been assessed. in addition, the optimal duration of the treatment has not been assessed. the lack of randomized controlled trial in cce precludes significant advances. the investigators decided to assess whether prednisone started early, at mild dosage and for a short period prevents death and progression to end-stage renal failure in patients with severe cce, as compared to placebo.

Eligibility criteria:
inclusion criteria: * biopsy-proven cce or clinically diagnosed cce as assessed on the 3 following criteria : presence of one or more precipitating factors renal function deterioration in atherosclerotic patients ischemic changes of the extremities or demonstration of retinal embolism * severe cce as defined by either acute renal failure (s creatinine \> 125 micromol/l and increase \> 25 % of baseline), or severe abdominal changes (hemorrhage, infarction, perforation or weight loss \> 5 % of body weight) or severe central nervous system neurological complication exclusion criteria: * cce unproven, or restricted to one organ, or non-active contraindication to prednisone.

Keywords: embolism cholesterol cristal creatinine renal insufficiency prednisone systemic atheroembolism
advance care planning with older patients who have end-stage kidney disease

Conditions: Kidney Failure, Chronic

Summary: this study will test the feasibility of carrying out a randomised controlled trial, incorporating a mixed methods process evaluation, to evaluate advance care planning with older patients who have end-stage kidney disease.

kidney failure becomes more common as people age. it increases the risks of other major illnesses, sudden worsening of symptoms, and death. even so, many people with kidney failure do not talk about their preferences for end-of-life care. advance care planning (acp) can help patients and families think through their preferences for future care and discuss these with the professionals looking after them. this may lead to care more in keeping with patients' wishes and so reduce distress for patients and families. acp is recommended as good practice for people with kidney failure. however, questions remain about the impact of acp on patients and families; and also about the best ways to put acp into practice. doing research about acp is challenging for everyone involved, so we need to thoroughly test our research methods in a pilot study before we attempt a larger study that would fully answer those questions. to test our methods we will carry out a small-scale randomised controlled trial comparing those patients who use acp with those who do not, in terms of: quality of life, anxiety, depression, physical functioning, well-being, satisfaction with decision-making and agreement between the patient and their nominated carer in terms of the patient's preferences for care at the end of life.

Eligibility criteria:
inclusion criteria: * attending the renal units taking part in the study * receiving renal replacement therapy * capacity to understand, retain, and weigh the necessary information and communicate their decisions * identified by their consultant as having worsening symptoms, functional decline, and two or more co-morbidities. exclusion criteria: * expected to die in the next three months

Keywords: advance care planning palliative care frail elderly renal dialysis
post-icu consultation : a time to discuss advance directives (coprada)

Conditions: Advance Directives; Post Intensive Care Syndrome; Advance Care Planning

Summary: the aim of this study is to assess the possibility of discussing advance directives during post-intensive care consultation.

after a stay in intensive care units (icu), patients can experience physical, psychological and cognitive impairments. to assess this post intensive care syndrom (pics), post-icu consultation have been developed. since 5 year mortality is higher in icu survivors, it might be interesting to address those patients' views relating to illness and end of life through a discussion on advance directives (ad), during post-icu consultation. however, the development of these consultations being recent, it has not yet been assessed whether this consultations might be a suitable time to discuss ad and the intensivit a suitable interlocutor.

Eligibility criteria:
inclusion criteria: * patients with 48 hours of mechanical ventilation * patients with a 5 days stay in icu exclusion criteria: * patients with therapeutic limitation discussed during their icu stay * geographical remotness to come to the post-icu consultation * minor patients * patient not affiliated to the social security scheme

Keywords: intensive care advance directives post intensive care syndrome post intensive care consultation
digital cbt-i for chronic insomnia

Conditions: Insomnia Chronic; Insomnia Disorder

Summary: this study evaluates the effectiveness and safety of a digital cognitive behavioral therapy program for insomnia (cbt-i) in individuals with chronic insomnia. participants will be randomly assigned to either begin digital cbt-i immediately or join a wait-list.

this multi-site, randomized, wait-list controlled trial investigates the effectiveness and safety of a digital cognitive behavioral therapy for insomnia (cbt-i) program in treating chronic insomnia. participants will be randomly assigned to start the digital cbt-i immediately or after a wait period. the digital cbt-i program, includes modules on sleep education, cognitive restructuring, stimulus control, sleep restriction, and relaxation techniques. primary and secondary outcomes will measure insomnia severity, beliefs about sleep, daytime sleepiness, mood, quality of life, productivity, and sleep efficiency. findings aim to assess the effectiveness of digital cbt-i in improving sleep and daily functioning among chronic insomnia patients in south korea.

Eligibility criteria:
inclusion criteria: * meets diagnostic criteria for insomnia disorder according to the international classification of diseases, 10th revision (icd-10), including: f51: nonorganic sleep disorders; g47: sleep disorders * has experienced insomnia symptoms for 3 months or longer. * scores 8 or higher on the insomnia severity index (isi). * oral and written fluency in korean * owns a smartphone and is independently able to use apps on a smartphone. * voluntarily agrees to participate in this clinical study and provides signed informed consent. exclusion criteria: * currently receiving non-pharmacological treatments for insomnia (e.g., cbt-i, light therapy, traditional medicine for sleep) within the past 3 months from screening. * diagnosed with other sleep disorders aside from insomnia and currently symptomatic, such as: * obstructive sleep apnea (g47.30) * sleep behavior disorders * restless leg syndrome (g28.8) * narcolepsy (g47.4) * has an active, ongoing physical illness that impedes daily functioning, such as: * congestive heart failure * chronic obstructive pulmonary disease (copd) * acute pain * neurological disorders (e.g., cerebrovascular disease) * neurodegenerative disorders (e.g., dementia, multiple sclerosis) * unstable medical conditions or life expectancy of less than 6 months * adjustments in schedule or dosage of sleep medications, antidepressants, anticonvulsants, anxiolytics, or antipsychotics within the past 3 months, or use of prn (as needed) prescribed sleep medications. * engaged in shift work. * pregnant individuals or those planning to become pregnant during the study period. * any condition that the investigator believes would make participation in the study not in the best interest of the participant or would preclude successful completion of study activities
french registry of acute st-elevation or non-st-elevation myocardial infarction 2015

Conditions: Myocardial Infarction

Summary: over the last two decades, considerable progress has been made in the management of myocardial infarction, both in the acute phase and in monitoring beyond the hospital phase. however changing practices in the "real world" and their impact on prognosis in the medium and long term patients admitted to the intensive care unit for acute myocardial infarction are relatively little studied exhaustively. the study of clinical, biological and genetic characteristics of patients and their conditions of care, help to identify patients at risk for increased morbidity and mortality after myocardial infarction and could be the basis for the subsequent realization of specific studies on the optimal therapeutic management of the disease according to the different risk profiles.

this is a multicenter observational study, given to 300 prospective medical facilities, including a clinic or intensive care unit entitled to receive emergency acute coronary syndromes. patients will be recruited consecutively during a period of 2 months. annual follow-ups will be conducted during 10 years of clinical research technicians of the french society of cardiology, mail and / or telephone contact with the municipalities of birth, treating physicians and patients. the ambition of the 2015 observatory of the french society of cardiology is through a photograph "scale" of the practices in france at present, to ensure consistency in the quality of care for hospitalized patients heart attack; the investigation will emphasize the strengths but also the weaknesses of our health care system so that should improve. finally, the observation of a large population of the real world will give the opportunity to assess the interactions between the different types of treatments used and check their possible synergy or incompatibilities.

Eligibility criteria:
inclusion criteria: 1. male or female aged over 18 years 2. patients admitted within 48 hours of onset of symptoms in a coronary intensive care unit (usic) for acute myocardial infarction (mi) defined by: a rise and fall of typical troponin (or cpkmb) associated with at least one of the following: * symptoms consistent with myocardial ischemia * development of pathological q waves * repolarisation disorders related to ischemia (or in addition to st depression, t wave inversion) 3. and having agreed to participate in the study. exclusion criteria: 1. refusal to consent 2. mi occurring in the 48 hours after therapeutic intervention (bypass surgery or coronary angioplasty or other surgical procedure) 3. diagnosis of myocardial reversed in favor of an alternative diagnosis

Keywords: acute coronary syndrome cardiology
a non-interventional study of treatment pattern and clinical outcomes in chinese participants with gastric cancer

Conditions: Gastric Cancer

Summary: this prospective, multi-center, non-interventional study will evaluate the efficacy and safety of trastuzumab in routine clinical practice in chinese participants with gastric or gastro-oesophageal cancer. the study will be conducted in 5 cohorts and eligible participants will be enrolled and assigned to the various cohorts according to human epidermal growth factor receptor 2 (her2) status, disease stage and treatment with trastuzumab according to physician's decision. treatment patterns and clinical outcomes in participants with gastric cancer in china will be evaluated. the total study duration is 60 months.


Eligibility criteria:
inclusion criteria: general inclusion criteria: * histologically confirmed cancer of the stomach or gastro-oesophageal junction or recurrent disease within 6 months before the date of recruitment * documented participant with trackable medical records * her2 status by immunohistochemistry (ihc) is known specific inclusion criteria: * cohort i/ii/iv: participants with mgc: with recurrent or metastatic disease or with inoperable locally advanced disease * cohort iii/v: participants with operable non-mgc: txnxm0 (according to american joint committee on cancer \[ajcc\] edition 7th) exclusion criteria: * participants receiving regimen in a blinded trial
newly diagnosed glioblastoma

Conditions: Glioblastoma

Summary: addition of anlotinib hydrochloride to the stupp regimen versus the stupp regimen alone for newly diagnosed glioblastoma.take pfs as the main evaluation index, the purpose is to evaluate its effectiveness


Eligibility criteria:
inclusion criteria: * understood and signed an informed consent form., with good compliance * age: 18-75 years old；.eastern cooperative oncology group (ecog) performance status of 0 to 2；life expectancy of at least 3 months. * glioblastoma confirmed by histology ; * random time is 4-6 weeks from the last operation , and the investigator judges that the surgical wound has healed well; * within 5 days before administration, the dosage of corticosteroids was stable or gradually decreased; * male or female subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study ；not pregnant or breastfeeding women,pregnancy before pregnancy screening, the women who blood / urine results were positivetherapy. exclusion criteria: * have previously received systemic radiotherapy and chemotherapy for gbm; * idh1/2 mutations are present * contraindicated for mri examination * the tumor only occurs in the brain stem * radiologically obvious diffuse meningeal dissemination * imaging shows that the tumor has invaded the periphery of important blood vessels or the investigator judges that the tumor is very likely to invade important blood vessels and cause fatal hemorrhage, cerebrovascular malformations or other bleeding tendency during the subsequent study period; * patients with arterial or venous thromboembolic events occurred within 6 months, such as cerebrovascular accident , deep vein thrombosis and pulmonary embolism； * other malignant tumors have occurred or are currently present at the same time within 3 years. * there are many factors that affect oral medications ; * received anti-tumor chinese patent medicine which were approved by nmpa within 2 weeks before the start of the study. * a clear history of neurological or psychiatric diseases, moderate or higher epilepsy , moderate or higher aphasia or dementia * participated in other anti-tumor drug clinical trials within 4 weeks before grouping; * other conditions which are not fit for this study assessed by investigator.